<h4>Background</h4>In recent years, novel therapies targeting specific molecular pathways and immunotherapies have exhibited promising outcomes for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.